Data / Research funding / Coronaviruses Vaccines
Coronaviruses Vaccines: 299 NIH awards ($766.7M) to 158 organizations
299 NIH awards ($766.7M) in the NIH spending category Coronaviruses Vaccines, to 158 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
299 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| CoVPN LOC Cross-Protocol Infrastructure Supplement for GY15 and GY16 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $156,469,927 | March 30, 2022 | March 31, 2022 | COREY, LAWRENCE | reporter.nih.gov |
| CoVPN 5001 - A prospective study of acute immune responses to SARS-CoV-2 infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $57,987,348 | March 21, 2022 | March 31, 2022 | GILBERT, PETER B. | reporter.nih.gov |
| HVTN 405/HPTN 1901 (CoVPN) Characterizing SARS-CoV-2-specific Immunity in Convalescent Individuals: LC 3 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $54,331,950 | March 18, 2022 | March 31, 2022 | MCELRATH, MARGARET JULIANA | reporter.nih.gov |
| New Mexico IDeA Networks of Biomedical Research Excellence (INBRE) | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $20,744,885 | September 30, 2001 | March 31, 2029 | LUSETTI, SHELLEY | reporter.nih.gov |
| COVID-19: External Quality Assurance Program Oversight Laboratory (EQAPOL) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $20,632,183 | September 30, 2023 | September 29, 2024 | DENNY, THOMAS | reporter.nih.gov |
| DEVELOPMENT OF A VACCINE CANDIDATE FOR CORONAVIRUSES | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $15,898,493 | June 1, 2023 | May 31, 2026 | KRAMMER, FLORIAN | reporter.nih.gov |
| Understanding Influenza and SARS-CoV-2 vaccine responses, in vivo and in vitro | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,884,300 | September 1, 2003 | April 30, 2029 | DAVIS, MARK MORRIS | reporter.nih.gov |
| HEALTH Center for Addictions Research and Cancer Prevention | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2024 | $12,882,144 | September 8, 2020 | April 30, 2026 | BEECH, BETTINA M. | reporter.nih.gov |
| Respiratory pathogen-specific T cell signatures following vaccination, natural infection, and treatment | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,580,221 | June 1, 2025 | May 31, 2027 | SETTE, ALESSANDRO | reporter.nih.gov |
| Center for Redox Biology and Cardiovascular Disease | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $12,065,347 | February 1, 2018 | June 30, 2028 | KEVIL, CHRISTOPHER G | reporter.nih.gov |
| Viral Immunity and VAccination (VIVA) Human Immunology Project Consortium (HIPC) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $9,862,919 | March 22, 2022 | February 28, 2027 | FERNANDEZ-SESMA, ANA | reporter.nih.gov |
| Task V34: Master Cell Banks Manufacturing for Next Generation SARS-CoV-2 Vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $8,647,922 | May 15, 2018 | May 14, 2028 | TRUSHEIM, HEIDI | reporter.nih.gov |
| Adjuvant Development of the TLR4 Ligand BECC470s For Use in Influenza, S. aureus, and P. aeruginosa Vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $7,143,498 | September 30, 2023 | September 29, 2028 | SORENSON, GREGORY | reporter.nih.gov |
| ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $6,937,118 | September 30, 2023 | September 29, 2026 | COLLINS, NICOLAS | reporter.nih.gov |
| Development of a COVID-19 Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $6,733,518 | September 1, 2020 | October 31, 2023 | REED, STEVEN | reporter.nih.gov |
| Task A68: Screening Vaccine (and Other Biologics) Platform Technologies using Coronavirus Mouse Immunogenicity as a Model System | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,550,363 | May 23, 2022 | September 30, 2026 | GRAHAM, RACHEL | reporter.nih.gov |
| TO IDENTIFY NOVEL ADJUVANT CANDIDATES THAT CAN BE USED TO AUGMENT THE EFFICACY OF HUMAN VACCINES. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $6,022,974 | September 30, 2019 | April 30, 2026 | CARSON, DENNIS | reporter.nih.gov |
| Discovery of adjuvants via novel modulation of innate immune pathways for vaccines against influenza | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,841,904 | September 30, 2019 | April 30, 2026 | ESSER-KAHN, AARON | reporter.nih.gov |
| Immune Cells and Secretory Pathways Leading to Human Systemic Autoimmunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,112,288 | May 1, 2019 | April 30, 2029 | PASCUAL, MARIA VIRGINIA | reporter.nih.gov |
| PROJECT MANAGEMENT SUPPORT FOR COMMUNITY ENGAGEMENT ON TRANS-NIH THERAPEUTICS AND VACCINE TRIALS | NIH | National Heart, Lung, and Blood Institute | 2021 | $4,297,649 | July 29, 2020 | January 28, 2021 | SHINGLEDECKER, DANIEL | reporter.nih.gov |
| Structure and Dynamics of the SARS-CoV-2 Spike Protein | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,142,443 | July 12, 2021 | June 30, 2027 | MOTHES, WALTHER H | reporter.nih.gov |
| Discovery of Adjuvants for mRNA Vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,882,045 | September 30, 2025 | September 29, 2026 | CARSON, DENNIS | reporter.nih.gov |
| Understanding Pandemic Evolution through Networked Data (UPEND) | NIH | National Institute of Mental Health | 2023 | $3,822,251 | April 15, 2023 | April 14, 2026 | CROWELL, TREVOR ADAM | reporter.nih.gov |
| Immune response to COVID-19 vaccine in HIV infected men and women | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,779,701 | September 23, 2021 | August 31, 2026 | RINALDO, CHARLES R | reporter.nih.gov |
| Development of a novel adjuvant strategy enabled by modulation of the physical properties of fungal mannans | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,755,681 | September 17, 2021 | August 31, 2026 | ZANONI, IVAN | reporter.nih.gov |
| Family-focused vs. Drinker-focused Smartphone Interventions to Reduce Drinking-related Consequences of COVID-19 | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2024 | $3,648,087 | September 25, 2021 | August 31, 2025 | GUSTAFSON, DAVID H | reporter.nih.gov |
| The generation and protective function of lung tissue resident memory T cells following SARS-CoV-2 infection or vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,543,436 | March 1, 2022 | February 28, 2027 | TEIJARO, JOHN ROSS | reporter.nih.gov |
| Community-Centered Interventions for Improved Vaccine Uptake for COVID (CIVIC) | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2025 | $3,378,034 | April 26, 2021 | May 9, 2025 | MARSH, ERICA E | reporter.nih.gov |
| SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,300,000 | August 17, 2023 | July 31, 2026 | ALPERT, MICHAEL DAVID | reporter.nih.gov |
| Brief digital intervention to increase COVID-19 vaccination among individuals with anxiety or depression | NIH | National Institute of Mental Health | 2022 | $3,296,734 | September 1, 2022 | March 11, 2025 | NASH, DENIS | reporter.nih.gov |
| Palliative Care Research Cooperative Group (PCRC): Refinement and Expansion | NIH | National Institute of Nursing Research | 2021 to 2022 | $3,268,072 | September 28, 2013 | June 30, 2023 | KUTNER, JEAN S | reporter.nih.gov |
| Engineering the Skin Immune System to Induce Systemic Immune Responses | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $3,251,899 | March 4, 2021 | January 31, 2027 | FALO, LOUIS D | reporter.nih.gov |
| Evolution of T cell immunity in blood and tissues over childhood | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,243,813 | March 16, 2022 | February 28, 2027 | FARBER, DONNA L. | reporter.nih.gov |
| To Develop and Manufacture an Inactivated SARS-CoV-2 Vaccine Using Blood Pathogen Reduction Technology | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,181,780 | September 1, 2020 | April 30, 2026 | GOODRICH, RAYMOND | reporter.nih.gov |
| Early life B cell responses and inflammation following SARS-CoV-2 infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,160,521 | September 17, 2021 | August 31, 2026 | FOUDA AMOU OU, GENEVIEVE GINY | reporter.nih.gov |
| System Biological Analyses of Innate and Adaptive Responses to Vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $3,147,703 | March 1, 2021 | June 30, 2023 | PULENDRAN, BALI | reporter.nih.gov |
| Structural interrogation of vaccine- and infection-induced B cell responses | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,116,277 | February 22, 2022 | January 31, 2027 | BAJIC, GORAN | reporter.nih.gov |
| The impact of T cell selection on vaccine durability | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,085,906 | September 24, 2021 | August 31, 2027 | SU, LAURA | reporter.nih.gov |
| Project 2VIDA! SARS-CoV-2 Vaccine Intervention Delivery for Adults in Southern California | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2025 | $3,077,210 | April 23, 2021 | January 31, 2027 | SKAATHUN, BRITT | reporter.nih.gov |
| Novel delivery platform and antigen design for an effective COVID-19 vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,066,236 | August 11, 2020 | July 31, 2027 | MITTAL, SURESH K | reporter.nih.gov |
| Using Disadvantage Indices in Pandemic Vaccine Allocation and Beyond to Promote Health Opportunity | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,031,954 | July 1, 2022 | June 30, 2027 | SCHMIDT, THOMAS HARALD | reporter.nih.gov |
| Clonal Dynamics of the antibody response | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,017,736 | January 1, 2017 | December 31, 2026 | VICTORA, GABRIEL D | reporter.nih.gov |
| Increasing Availability of Emulsion Adjuvants via Synthetic Biology | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $2,996,311 | August 30, 2022 | August 29, 2025 | KEMPINSKI, CHASE | reporter.nih.gov |
| A Phylodynamic Artificial Intelligence framework to predict evolution of SARS-CoV-2 variants of concern in Immunocompromised persons with HIV (PhAI-CoV) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,985,316 | July 12, 2022 | June 30, 2027 | SALEMI, MARCO | reporter.nih.gov |
| Developing a Multi-epitope Pan-Coronavirus Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,944,787 | August 7, 2020 | July 31, 2025 | BENMOHAMED, LBACHIR | reporter.nih.gov |
| REDES: a peer network and mobile health (mHealth) enhanced CHW model to maximize COVID-19 vaccination among low income Latinos | NIH | National Institute on Minority Health and Health Disparities | 2022 to 2025 | $2,925,112 | April 13, 2022 | October 31, 2027 | PAGE, KATHLEEN R | reporter.nih.gov |
| Combined adjuvant approaches for enhancement of SARS-CoV-2 vaccine efficacy | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,917,054 | June 1, 2022 | May 31, 2027 | WONG, PAMELA TINMOI | reporter.nih.gov |
| Community-based Design and Evaluation of a Conversational Agent to Promote SARS-COV2 Vaccination in Black Churches | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2024 | $2,872,823 | April 23, 2021 | April 1, 2025 | BICKMORE, TIMOTHY W. | reporter.nih.gov |
| A Phase 1/2a, randomized study of a Tfh-targeting genetic vaccine adjuvant designed to induce broad, durable immune responses | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,852,667 | May 7, 2024 | April 30, 2029 | CHEW, KARA W | reporter.nih.gov |
| The longer-term impact of prenatal exposure to SARS-CoV-2 infection and the COVID-19 vaccine on behavior, cognition, and brain functioning in the child | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2025 | $2,848,362 | August 19, 2022 | June 30, 2027 | ROMMEL, ANNA-SOPHIE | reporter.nih.gov |
| Long-term Suppressive Valacyclovir Treatment for Herpes Zoster Ophthalmicus | NIH | National Eye Institute | 2022 to 2023 | $2,806,822 | September 30, 2016 | July 31, 2023 | COHEN, ELISABETH J | reporter.nih.gov |
| Modeling the Coupled Dynamics of COVID-19 Transmission and Protective Behaviors | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,758,288 | September 17, 2021 | August 31, 2027 | PARKER, ANDREW | reporter.nih.gov |
| Antibody Durability Dynamics | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,745,532 | July 1, 2022 | June 30, 2027 | WESEMANN, DUANE R. | reporter.nih.gov |
| Alaska Native Communities Advancing Vaccine Uptake | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,702,576 | August 18, 2022 | July 31, 2027 | BEANS, JULIE | reporter.nih.gov |
| A risk-varying and perturbed self-controlled case series design for assessing the safety of COVID-19 vaccines in a large health care system | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,691,275 | May 17, 2022 | April 30, 2027 | XU, STANLEY | reporter.nih.gov |
| COVID Transmission and Morbidity in Malawi (COVID-TMM) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,666,340 | April 1, 2025 | March 31, 2027 | VALIM, CLARISSA | reporter.nih.gov |
| Fusion peptide directed immunogens that elicit neutralizing and protective antibodies in non-human primates | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,658,042 | March 18, 2019 | February 28, 2025 | WARD, ANDREW BARRETT | reporter.nih.gov |
| Regulation of germinal center responses by SARS-CoV-2 messenger RNA vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,622,660 | February 9, 2022 | January 31, 2027 | LOCCI, MICHELA | reporter.nih.gov |
| Systems modeling to address the social and biological drivers of disparities in infection and mortality from emerging infectious diseases | NIH | National Institute on Minority Health and Health Disparities | 2022 to 2025 | $2,614,508 | July 20, 2022 | November 30, 2027 | ZELNER, JONATHAN L | reporter.nih.gov |
| Wirelessly controlled BSL3 vivarium system for automated microdosing in studies of infectious diseases | NIH | Office of the Director, National Institutes of Health | 2021 to 2022 | $2,495,626 | August 1, 2021 | July 31, 2025 | HOANG, TUAN Q | reporter.nih.gov |
| K-VAC: Kentucky Vaccinating Appalachian Communities | NIH | National Institute on Minority Health and Health Disparities | 2022 to 2025 | $2,489,189 | July 15, 2022 | March 31, 2028 | KIVINIEMI, MARC T | reporter.nih.gov |
| Development of a Safe and Potent Vaccine Against Melioidosis using the LVS dcapB Vector Platform | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,482,547 | June 1, 2019 | May 31, 2025 | HORWITZ, MARCUS AARON | reporter.nih.gov |
| Control of Humoral and Cellular Immunity to Viral Infections of the Lung by Follicular CD8 T Cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,450,710 | April 1, 2021 | March 31, 2026 | SAGE, PETER THE | reporter.nih.gov |
| SARS-CoV-2 Vaccine Responses in children with genetic or acquired B cell deficiencies | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,443,721 | June 2, 2022 | May 31, 2026 | HSIEH, WEN-YUAN E | reporter.nih.gov |
| Longitudinal SARS-CoV-2 mRNA vaccine-induced mucosal, serological, and cellular immunity in children and human milk | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,395,128 | September 21, 2022 | July 31, 2027 | PANNARAJ, PIA S | reporter.nih.gov |
| Investigating and identifying the heterogeneity in COVID-19 misinformation exposure on social media among Black and Rural communities to inform precision public health messaging | NIH | National Institute on Minority Health and Health Disparities | 2022 to 2024 | $2,356,413 | September 20, 2022 | March 20, 2025 | GUNTUKU, SHARATH CHANDRA | reporter.nih.gov |
| Scaling and Sustaining COVID-19 Vaccination through Meaningful Community Engagement and Care Coordination for Underserved Communities | NIH | National Institute on Minority Health and Health Disparities | 2022 to 2025 | $2,271,972 | September 26, 2022 | June 30, 2027 | STADNICK, NICOLE A | reporter.nih.gov |
| LatiNET, a Multilevel Social Network Model to Examine and Address SARS-CoV-2 Misinformation in Low-Income Latinx Communities. | NIH | National Institute on Minority Health and Health Disparities | 2022 to 2024 | $2,250,728 | September 20, 2022 | April 1, 2025 | KANAMORI NISHIMURA, MARIANO JUAN | reporter.nih.gov |
| Leveraging Community-Academic Partnerships and Social Networks to Disseminate Vaccine-Related Information and Increase Vaccine Uptake Among Black Individuals with Rheumatic Diseases | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2024 | $2,239,160 | May 10, 2022 | April 1, 2025 | RAMSEY-GOLDMAN, ROSALIND | reporter.nih.gov |
| Trusted Messengers: Supporting Physicians in Promoting COVID-19 Vaccination | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2023 | $2,238,005 | May 17, 2021 | February 28, 2025 | FISHER, KIMBERLY | reporter.nih.gov |
| Immunological drivers of the transition from epidemicity to endemicity of SARS-CoV-2 in a high transmission LMIC setting | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,222,713 | February 21, 2023 | January 31, 2028 | KO, ALBERT ICKSANG | reporter.nih.gov |
| Immunologic and Clinical Sequelae after COVID-19 in Patients with Systemic Autoimmune Rheumatic Diseases | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2025 | $2,205,056 | February 1, 2023 | January 31, 2028 | SPARKS, JEFFREY ANDREW | reporter.nih.gov |
| COVID-19 Vaccine Effectiveness in Pregnant Women and their Infants | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,181,493 | March 10, 2022 | February 28, 2027 | ZERBO, OUSSENY | reporter.nih.gov |
| AI-based platform for predicting emerging vaccine-escape variants and designing mutation-proof antibodies | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,174,184 | May 6, 2022 | April 30, 2027 | WEI, GUOWEI | reporter.nih.gov |
| Mechanisms of protective memory CD8 T-cell induction by mRNA-LNP vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,140,211 | June 1, 2023 | May 31, 2028 | SIGAL, LUIS J | reporter.nih.gov |
| Impact of immune sex differences in the first 1000 days of life and in childhood and adolescence | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,131,407 | June 17, 2022 | May 31, 2027 | GOULDER, PHILIP J | reporter.nih.gov |
| Influenza & COVID Obstetric and Perinatal Epidemiology Study in India | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2025 | $2,121,321 | September 23, 2022 | August 31, 2027 | HIBBERD, PATRICIA L | reporter.nih.gov |
| Determinants of Convalescent and Vaccine-induced Mucosal Specific Immunity to SARS-CoV-2 and Variants of Concern in Children with Asthma | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,083,062 | February 1, 2023 | January 31, 2028 | TEAGUE, WILLIAM GERALD | reporter.nih.gov |
| Statistical Methods for Efficacy Trials of Vaccines and Monoclonal Antibodies Against Genetically-Diverse Pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,067,031 | April 1, 2003 | June 30, 2029 | GILBERT, PETER B. | reporter.nih.gov |
| Investigating the role of maternal-fetal crosstalk on neonatal immunity in COVID-19 infection or vaccination in pregnancy | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 to 2025 | $2,064,368 | April 1, 2023 | January 31, 2028 | GAW, STEPHANIE LINA | reporter.nih.gov |
| Maternal COVID-19 Vaccination and Lactation Outcomes | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2024 | $2,020,105 | July 1, 2022 | March 10, 2025 | PALMSTEN, KRISTIN | reporter.nih.gov |
| Determinants of Early Childhood Immune Responses | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 to 2025 | $2,017,519 | September 20, 2023 | June 30, 2028 | PRAHL, MARY | reporter.nih.gov |
| Community Developed Technology-Based Messaging to Increase SARS-CoV-2 Vaccine Uptake Among People Who Inject Drugs | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,984,874 | June 1, 2021 | April 30, 2024 | ARONSON, IAN DAVID | reporter.nih.gov |
| Porous silicon microparticle-based subunit vaccines for SARS-CoV-2 | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,965,558 | February 10, 2023 | January 31, 2028 | WANG, TIAN | reporter.nih.gov |
| Development of a rapid response nucleic acid vaccine strategy for coronavirus epidemics | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,955,395 | June 2, 2020 | April 30, 2023 | BAGLEY, KENNETH C | reporter.nih.gov |
| PROmotion of COVid-19 VA(X)ccination in the Emergency Department - PROCOVAXED | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,899,293 | May 24, 2021 | March 10, 2025 | RODRIGUEZ, ROBERT | reporter.nih.gov |
| Improving COVID-19 Vaccine Uptake Among Racial and Ethnic Minority Groupswith Rheumatic Diseases | NIH | National Institute on Minority Health and Health Disparities | 2023 to 2025 | $1,876,437 | August 17, 2023 | May 31, 2028 | DANILA, MARIA IOANA | reporter.nih.gov |
| A structural HIV prevention intervention targeting high-risk women | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,872,697 | September 15, 2021 | August 31, 2024 | SHERMAN, SUSAN G. | reporter.nih.gov |
| Addressing COVID 19 Vaccine Hesitancy in Rural Community Pharmacies Reducing Disparities Through an Implementation Science Approach | NIH | National Institute on Minority Health and Health Disparities | 2022 to 2024 | $1,860,412 | September 22, 2022 | April 1, 2025 | CARPENTER, DELESHA MILLER | reporter.nih.gov |
| Increasing COVID-19 Vaccine Uptake among Latinos through a Targeted Clinical and Community-behavioral Intervention | NIH | National Institute on Minority Health and Health Disparities | 2022 to 2024 | $1,853,556 | August 21, 2022 | April 30, 2025 | CRESPO, NOE CUAUHTEMOC | reporter.nih.gov |
| Behavioral and Social Science Research to Optimize SARS-CoV-2 Protective Vaccine Uptake in Racial Minority Communities with High Rates of COVID-19 | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2023 | $1,851,350 | September 19, 2021 | May 31, 2025 | KELLY, JEFFREY A | reporter.nih.gov |
| Medical Mistrust as a Barrier to COVID-19 and HIV Services Among Transgender Women of Color | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2022 | $1,832,227 | September 11, 2018 | April 30, 2024 | DUNCAN, DUSTIN T | reporter.nih.gov |
| Unraveling Human T Follicular Helper Cell Development | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,813,149 | December 6, 2022 | November 30, 2027 | MUDD, PHILIP A | reporter.nih.gov |
| Addressing Vaccine AcceptaNce in Carceral Settings through Community Engagement (ADVANCE) | NIH | National Institute on Minority Health and Health Disparities | 2022 to 2024 | $1,811,735 | September 26, 2022 | December 31, 2026 | PUGLISI, LISA BALZANO | reporter.nih.gov |
| Connecting the Dots: HIV, COVID-19, and Structural Racism in Gender Minority Women | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2022 | $1,810,877 | September 1, 2018 | March 31, 2024 | PERREIRA, KRISTA M | reporter.nih.gov |
| Cohort and biomarkers for COVID-19 severity, natural history, and reinfection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $1,790,574 | September 17, 2021 | August 31, 2025 | BLASER, MARTIN J | reporter.nih.gov |
| Transmission of CoV-2 and the Impact of Spike Protein Evolution | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,714,785 | July 1, 2023 | June 30, 2027 | BOON, ADRIANUS CM | reporter.nih.gov |
| Leveraging community-based behavioral health to increase vaccine uptake in Latinx adults with mental illness | NIH | National Institute of Nursing Research | 2022 to 2024 | $1,714,097 | September 26, 2022 | March 10, 2025 | DAVISON, KIRSTEN | reporter.nih.gov |
| Vaccination responses in lung transplant recipients | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $1,708,641 | August 5, 2022 | July 31, 2027 | NICOLLS, MARK ROBERT | reporter.nih.gov |
| A COVID-19 Point of Care Serological Assay for Rapid Quantification of Antibody Titer. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,700,055 | February 3, 2021 | January 31, 2025 | GANDINI, ALBERTO | reporter.nih.gov |
| COVID Global Mix - Global Mix / Investigation of COVID-19 Disease Parameters for Transmission Models in Low-Resource Settings | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,692,497 | March 1, 2025 | February 28, 2027 | OMER, SAAD B. | reporter.nih.gov |
| Phase 1 study of a SARS-CoV-2 vaccine adjuvanted via controlled biodistribution of mRNA encoding spike protein and IL-12p70 | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,673,641 | September 25, 2025 | July 31, 2030 | DOWLING, DAVID JAMES | reporter.nih.gov |
| Community Wise: An innovative multi-level intervention to reduce alcohol and illegal drug use | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2022 | $1,634,942 | May 16, 2016 | November 12, 2023 | WINDSOR, LILIANE CAMBRAIA | reporter.nih.gov |
| Immunogenetics of COVID-19 Immune Response | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,614,396 | August 1, 2024 | July 31, 2029 | KENNEDY, RICHARD B | reporter.nih.gov |
| Defining humoral correlates of immunity against COVID-19 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,591,400 | July 1, 2008 | December 31, 2022 | ALTER, GALIT | reporter.nih.gov |
| GMP production and GLP safety of bidirectionally targeted SARS-CoV-2 booster vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $1,571,691 | July 11, 2023 | June 30, 2025 | SPARGER, ELLEN ELIZABETH | reporter.nih.gov |
| COVID-19 Effects on the Mental and Physical Health of AAPI Survey Study (COMPASS) II | NIH | National Institute on Aging | 2021 | $1,548,746 | September 1, 2019 | May 31, 2023 | PARK, VAN MY TA | reporter.nih.gov |
| Reaching Communities through the Design of Information Visualizations (ReDIVis) Toolbox for Return of COVID-19 Results | NIH | National Institute of Nursing Research | 2021 to 2022 | $1,536,526 | August 16, 2016 | November 15, 2023 | BAKKEN, SUZANNE | reporter.nih.gov |
| Structure-based design of coronavirus subunit vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,525,013 | July 1, 2021 | April 30, 2025 | DU, LANYING | reporter.nih.gov |
| Mucosal subunit vaccines against SARS CoV-2 | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,514,869 | June 5, 2024 | April 30, 2029 | DUBEY, PURNIMA | reporter.nih.gov |
| Mechanisms of BNT162b2 Vaccine Immunogenicity in Systemic Lupus Erythematosus or Scleroderma | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,492,035 | March 4, 2024 | January 31, 2029 | UTZ, PAUL JOSEPH | reporter.nih.gov |
| Thermostabilized Subunit Glycoprotein Vaccine Platform: Immune Characterization of an Emulsified Adjuvant with SARS-CoV-2 Spike Protein and EBOV GP | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,466,410 | December 17, 2020 | November 30, 2023 | DONINI, OREOLA | reporter.nih.gov |
| Effects of Vaccination on Acute and Post-Acute Respiratory Viral Infection Outcomes in Solid Organ Transplant Recipients | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,442,898 | June 13, 2025 | May 31, 2030 | WERBEL, WILLIAM | reporter.nih.gov |
| A multidimensional Digital Approach to Address Vaccine Hesitancy and Increase COVID-19 Vaccine Uptake among African American Young Adults in the South | NIH | National Institute on Minority Health and Health Disparities | 2023 to 2024 | $1,441,224 | April 20, 2021 | April 1, 2025 | HIGHTOW-WEIDMAN, LISA B | reporter.nih.gov |
| Motivational Interviewing Training to Promote COVID-19 and Influenza Vaccination (MI-VAX): What Providers Need and Patients Want | NIH | National Institute on Minority Health and Health Disparities | 2024 to 2025 | $1,432,670 | June 27, 2024 | January 31, 2029 | FISHER, KIMBERLY | reporter.nih.gov |
| Development of pan-betacoronavirus vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,432,273 | March 3, 2023 | February 29, 2028 | ANDRABI, RAIEES AHMAD | reporter.nih.gov |
| A multidimensional Digital Approach to Address Vaccine Hesitancy and Increase COVID-19 Vaccine Uptake among African American Young Adults in the South | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2022 | $1,429,381 | April 20, 2021 | September 30, 2022 | HIGHTOW-WEIDMAN, LISA B | reporter.nih.gov |
| A deep learning and experiment integrated platform for stable mRNA vaccines development | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,428,493 | November 22, 2021 | October 31, 2026 | SUN, QING | reporter.nih.gov |
| Self-Assembling Spike-EBR Nanoparticles as a Vaccine Platform Technology Against SARS-CoV-2 and Future Pandemic Coronaviruses | NIH | Office of the Director, National Institutes of Health | 2024 to 2025 | $1,417,500 | June 22, 2024 | August 31, 2027 | HOFFMANN, MAGNUS ADRIAN GERO | reporter.nih.gov |
| Design and Analysis of Vaccine Trials for Emerging Infectious Disease Threats | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,403,064 | August 15, 2018 | July 31, 2025 | DEAN, NATALIE EXNER | reporter.nih.gov |
| Identifying salient factors that influence physician practices in mitigating patient misinformation | NIH | National Institute on Aging | 2024 to 2025 | $1,399,582 | June 15, 2024 | October 20, 2029 | MASTER, ZUBIN | reporter.nih.gov |
| Generation of robust resident memory T cells in barrier tissues through skin vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,375,733 | June 7, 2021 | November 30, 2022 | KUPPER, THOMAS S. | reporter.nih.gov |
| Dime la VerDAD (Verify, Debunk, and Disseminate) | NIH | National Institute on Minority Health and Health Disparities | 2023 to 2024 | $1,339,601 | July 10, 2023 | September 15, 2024 | DEL RIOS, MARINA | reporter.nih.gov |
| Influence of Social Media, Social Networks, and Misinformation on Vaccine Acceptance Among Black and Latinx Individuals | NIH | National Institute on Minority Health and Health Disparities | 2024 to 2025 | $1,334,938 | September 20, 2024 | April 30, 2029 | YOUNG, SEAN | reporter.nih.gov |
| Immunogenicity of lipid nanoparticles | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,318,898 | February 16, 2024 | December 31, 2028 | JIANG, SHAOYI | reporter.nih.gov |
| Rational design and evaluation of novel mRNA vaccines against MERS-CoV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,297,163 | July 1, 2021 | January 31, 2025 | DU, LANYING | reporter.nih.gov |
| Antibody repertoire characterization in the context of coronaviruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,283,747 | July 28, 2020 | May 31, 2023 | GEORGIEV, IVELIN | reporter.nih.gov |
| Uptake, Safety and Effectiveness of COVID‐19 Vaccines during Pregnancy | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $1,277,429 | April 8, 2022 | March 31, 2025 | REGAN, ANNETTE KARENA | reporter.nih.gov |
| Systems analyses of induction and maintenance of immunity to SARS-CoV-2 vaccination in kidney transplant recipients receiving mycophenolate mofetil immunotherapy | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,264,269 | March 1, 2024 | February 28, 2029 | REED, ELAINE F | reporter.nih.gov |
| Real-world impact of the COVID-19 pandemic in people with multiple sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2024 | $1,195,081 | January 15, 2022 | June 30, 2025 | XIA, ZONGQI | reporter.nih.gov |
| Getting Asian Americans INFORMED to Facilitate COVID-19 Testing and Vaccination | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,135,235 | September 1, 2014 | May 31, 2024 | TSOH, JANICE Y | reporter.nih.gov |
| Technical and Administrative Management Services in Support of Domestic and International Collaborative Research Efforts | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,125,216 | October 1, 2016 | July 12, 2022 | HAMRICK, SOMER | reporter.nih.gov |
| Maternal Fetal Medicine Units Network: University of California, San Francisco | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 to 2025 | $1,065,900 | April 1, 2023 | March 31, 2030 | NORTON, MARY E | reporter.nih.gov |
| COVID-19 - Global Mix / Investigation of COVID-19 Disease Parameters for Transmission Models in Low-Resource Settings | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $1,055,903 | March 1, 2022 | May 31, 2023 | OMER, SAAD B. | reporter.nih.gov |
| Final Preclinical Testing and Formulation of a Scalable, Live-attenuated SARS-CoV-2 Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $999,267 | May 6, 2021 | April 30, 2023 | MUELLER, STEFFEN | reporter.nih.gov |
| Hotspots_COVID Supplement II | NIH | National Institute of General Medical Sciences | 2021 to 2022 | $969,908 | August 15, 2014 | March 31, 2024 | VULLIKANTI, ANIL | reporter.nih.gov |
| Innate Control of Adaptive Immunity to SARS-CoV-2 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $968,772 | June 1, 2021 | May 31, 2026 | GOLDMAN-ISRAELOW, BENJAMIN | reporter.nih.gov |
| Health Services Utilization During the COVID-19 Pandemic | NIH | National Institute on Aging | 2022 to 2023 | $966,092 | September 30, 2022 | February 25, 2024 | WHALEY, CHRISTOPHER | reporter.nih.gov |
| Protection of at-risk low birth weight infants against influenza via maternal antibody | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $942,300 | June 1, 2021 | May 31, 2026 | KACHIKIS, ALISA | reporter.nih.gov |
| Mentoring in Patient-Oriented HIV Research in the Era of Universal ART | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $928,483 | March 1, 2017 | June 30, 2027 | LOCKMAN, SHAHIN | reporter.nih.gov |
| Vaccine Hesitancy: Exploring the Role of Temporal and Cross-country Variation in COVID Rules, Vaccine Media Coverage, and Public Health Policy Consistency | NIH | National Institute on Aging | 2023 | $885,000 | August 15, 2023 | July 31, 2025 | LILLARD, DEAN R | reporter.nih.gov |
| Self-Assembling Spike-EBR Nanoparticles as a Vaccine Platform Technology Against SARS-CoV-2 and Future Pandemic Coronaviruses. | NIH | Office of the Director, National Institutes of Health | 2022 to 2023 | $842,000 | September 15, 2022 | May 31, 2024 | HOFFMANN, MAGNUS ADRIAN GERO | reporter.nih.gov |
| Immunologic mechanisms that prevent autoimmunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $816,829 | July 6, 2020 | January 31, 2024 | CANTOR, HARVEY | reporter.nih.gov |
| Development of pan-betacoronavirus vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $805,612 | March 3, 2023 | June 30, 2023 | ANDRABI, RAIEES AHMAD | reporter.nih.gov |
| Longitudinal SARS-CoV-2 mRNA vaccine-induced mucosal, serological, and cellular immunity in children and human milk | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $800,606 | September 21, 2022 | August 2, 2023 | PANNARAJ, PIA S | reporter.nih.gov |
| Cohort and biomarkers for COVID-19 severity, natural history, and reinfection | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $784,970 | September 17, 2021 | August 31, 2022 | BLASER, MARTIN J | reporter.nih.gov |
| Molecular determinants of vaccine-induced antibody durability | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $777,495 | September 20, 2025 | July 31, 2030 | SAJADI, MOHAMMAD MOHSENI | reporter.nih.gov |
| Rational design of a unique vaccine for emerging pandemic coronaviruses | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $755,225 | December 6, 2024 | November 30, 2029 | QIAO, LIANG | reporter.nih.gov |
| Development of Sustained-Release Anti-coronavirus Nucleoside Phosphonate compounds | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $749,444 | February 21, 2017 | January 31, 2022 | SCHOOLEY, ROBERT TURNER | reporter.nih.gov |
| A Tunable Nanophage Platform for Vaccine Development | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $726,000 | August 20, 2024 | July 31, 2025 | CATALANO, CARLOS ENRIQUE | reporter.nih.gov |
| SARS-CoV-2 vaccine durability during SIV infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $706,000 | August 1, 2023 | July 31, 2025 | O'CONNOR, MEGAN A | reporter.nih.gov |
| Coordination of innate and cellular mucosal immunity in SARS-CoV-2 clearance | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $705,557 | December 20, 2024 | November 30, 2029 | KOHLMEIER, JACOB E | reporter.nih.gov |
| Integrated Training Program in Vaccinology (ITP-Vax) | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $705,286 | August 15, 2024 | July 31, 2029 | HARRISON, SHANNON TAKALA | reporter.nih.gov |
| Optimizing mRNA sequences with deep neural networks | NIH | National Library of Medicine | 2024 to 2025 | $702,000 | August 26, 2024 | July 31, 2028 | ZHOU, XIAOBO | reporter.nih.gov |
| Implementation of a qPCR-based assay for the quantification of SARS-CoV-2-specific T cells in immunocompromised patients | NIH | National Cancer Institute | 2024 to 2025 | $700,716 | September 18, 2023 | August 31, 2027 | GUCCIONE, ERNESTO | reporter.nih.gov |
| Community - based behavioral intervention to increase COVID - 19 and influenza vaccination for African American/ Black and Latino persons: An optimization randomized controlled trial | NIH | National Institute on Minority Health and Health Disparities | 2024 | $688,573 | September 22, 2024 | April 1, 2025 | GWADZ, MARYA | reporter.nih.gov |
| Characterization and optimization of single dose, thermostable and durable vaccine platform towards increased clinical acceptance | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $668,569 | August 23, 2024 | June 30, 2029 | ZABALETA, NEREA | reporter.nih.gov |
| Evaluating Clinical and Immunological Consequences of SARS-CoV-2 Vaccination in Rheumatic Disease | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2024 | $655,352 | December 1, 2021 | November 30, 2025 | DOMSIC, ROBYN THERESE | reporter.nih.gov |
| A muco-penetrating biomaterial-based subunit vaccine for programming protective immune responses to SARS-CoV-2 | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2023 | $655,001 | July 1, 2021 | April 30, 2025 | WILSON, DAVID SCOTT | reporter.nih.gov |
| Immunomodulatory drug interventions for the prevention of host immune responses toward AAV-delivered anti-HIV antibodies | NIH | Office of the Director, National Institutes of Health | 2025 | $630,197 | February 1, 2025 | January 31, 2027 | FUCHS, SEBASTIAN PATRICK | reporter.nih.gov |
| Developing mRNAdesigner tool package for optimization of mRNA sequence | NIH | National Institute of General Medical Sciences | 2024 to 2025 | $624,000 | September 30, 2024 | June 30, 2028 | ZHOU, XIAOBO | reporter.nih.gov |
| Structure, Function and Antigenicity of Coronavirus Spike Proteins | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $613,032 | February 9, 2017 | January 31, 2023 | MCLELLAN, JASON SCOTT | reporter.nih.gov |
| SARS-CoV-2 in Pregnancy: Comparison of Natural Infection and Hybrid Immunity in Mother-Infant Pairs | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $610,740 | July 5, 2023 | June 30, 2028 | CAMBOU, MARY CATHERINE | reporter.nih.gov |
| Optimize Formulation of VSA Adjuvant | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $600,000 | July 5, 2022 | July 5, 2024 | CLEMENTS, DAVID | reporter.nih.gov |
| A Novel Multi-Epitope-Based Universal Vaccine Against Multiple Coronavirus Variants of Concern | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $600,000 | February 1, 2023 | January 31, 2026 | VAHED, HAWA | reporter.nih.gov |
| Double-Encapsulated mRNA Vaccine for COVID-19 | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $600,000 | March 3, 2023 | February 28, 2025 | CASTOR, TREVOR P. | reporter.nih.gov |
| Gene Gun-delivered RNA vaccines. | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $600,000 | May 3, 2024 | April 30, 2027 | FRIZZELL, HANNAH | reporter.nih.gov |
| Developing a Thermostable SARS-CoV-2 RBD-particle Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $599,982 | July 9, 2021 | June 30, 2024 | HUANG, WEI-CHIAO | reporter.nih.gov |
| Discovery of Isotucaresol derivatives as adjuvants for vaccines testing in a SARS-CoV-2 vaccine model | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $598,808 | September 1, 2021 | August 31, 2023 | RASHEED, OMER | reporter.nih.gov |
| MRNA VACCINE DEVELOPMENT | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $594,566 | September 1, 2024 | August 31, 2026 | ANDRIANOVA, KATERINA | reporter.nih.gov |
| RNA epigenetic modifications in SARS-CoV-2 | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $582,618 | February 1, 2025 | January 31, 2030 | LI, JIANRONG | reporter.nih.gov |
| Mechanisms of Immune Dysfunction in Oral Post-Acute Sequelae of Covid-19 | NIH | National Institute of Dental & Craniofacial Research | 2023 | $581,037 | September 13, 2023 | September 12, 2025 | NAQVI, AFSAR RAZA | reporter.nih.gov |
| Flow cytometer Cell Sorter for Biosafety Level-3 Facility | NIH | Office of the Director, National Institutes of Health | 2021 | $547,000 | May 1, 2021 | April 30, 2023 | GARG, ANKITA | reporter.nih.gov |
| Network Intervention Planning without Actual Network Data for Infectious Disease Control | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $538,884 | February 25, 2022 | January 31, 2027 | NISHI, AKIHIRO | reporter.nih.gov |
| Development of Broad Coronavirus Immunity Targeting the Fusion Peptide | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $503,332 | June 9, 2021 | May 31, 2023 | KULP, DANIEL | reporter.nih.gov |
| Characterization of seasonal CoV immunity and operationalization of a novel controlled human infection model for the betacoronavirus OC43 | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $502,779 | May 25, 2023 | April 30, 2027 | DEMING, MEAGAN ELISE | reporter.nih.gov |
| Shark nanobodies enable identification of pan-sarbecovirus and pan-merbecovirus spike RBD sites of vulnerability | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $494,974 | February 17, 2023 | January 31, 2025 | DOOLEY, HELEN M. | reporter.nih.gov |
| Design and development of a novel, thermostable, and inhalable dry powder COVID-19 vaccine | NIH | National Institute of General Medical Sciences | 2022 to 2024 | $492,000 | April 20, 2022 | March 31, 2026 | KUNDA, NITESH K | reporter.nih.gov |
| Integrated Network Analysis of RADx-UP Data to Increase COVID-19 Testing and Vaccination Among Persons Involved with Criminal Legal Systems (PCLS) | NIH | National Institute on Minority Health and Health Disparities | 2023 to 2024 | $486,899 | September 21, 2023 | April 1, 2025 | KHANNA, ADITYA SUBHASH | reporter.nih.gov |
| Identifying and evaluating prevention strategies for COVID-19 in correctional facilities | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $486,363 | August 4, 2023 | August 31, 2026 | LIND, MARGARET | reporter.nih.gov |
| Innate and adaptive defenses against SARS-COV-2 in the oral cavity during acute unvaccinated and breakthrough infections | NIH | National Institute of Dental & Craniofacial Research | 2022 | $483,000 | September 1, 2022 | August 31, 2024 | WEINBERG, AARON | reporter.nih.gov |
| Verification of pigs as an appropriate model for the development of human vaccines targeting the entero-mammary pathway to elicit a robust secretory IgA response in human milk | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $477,406 | September 3, 2025 | August 31, 2027 | POWELL, REBECCA | reporter.nih.gov |
| Defining the optimal type and timing of COVID-19 vaccine in pregnancy | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $475,475 | January 21, 2022 | December 31, 2024 | COLLIER, AI-RIS YONEKURA | reporter.nih.gov |
| Impact of mucosal adjuvanted vaccines on virus transmission in preclinical animal models for SARS-CoV-2 and influenza virus infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $472,250 | June 20, 2024 | April 30, 2026 | SCHOTSAERT, MICHAEL | reporter.nih.gov |
| Shielding Replicating Single-cycle Vaccines against SARS-CoV-2 | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $470,627 | August 17, 2023 | July 31, 2024 | BARRY, MICHAEL A | reporter.nih.gov |
| Integrated Analysis of SARS-CoV-2 Vaccine Responses During Aging | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $466,970 | September 15, 2021 | August 31, 2023 | SAGE, PETER THE | reporter.nih.gov |
| Comprehensive genomic and inflammatory profiling of vaccine-associated myocarditis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $464,750 | November 3, 2022 | October 31, 2025 | KONTOROVICH, AMY R. | reporter.nih.gov |
| The role of the mRNA-based or Newcastle disease virus (NDV)-based vaccine platform in mucosal B cell priming and recirculation | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $464,750 | July 23, 2025 | June 30, 2027 | SUN, WEINA | reporter.nih.gov |
| Epigenetic Histone Landscape Profiles in HIV | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $463,003 | July 21, 2022 | June 30, 2025 | UTZ, PAUL JOSEPH | reporter.nih.gov |
| Community Developed Technology-Based Messaging to Increase SARS-CoV-2 Vaccine Uptake Among People Who Inject Drugs | NIH | National Institute on Drug Abuse | 2024 | $461,653 | June 1, 2021 | April 1, 2025 | ARONSON, IAN DAVID | reporter.nih.gov |
| Serological and cellular immune response to SARS-CoV-2 vaccination in pediatric multiple sclerosis on immunotherapy | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $460,866 | July 1, 2024 | May 31, 2027 | GOMBOLAY, GRACE YOONHEEKIM | reporter.nih.gov |
| Deciphering the Molecular Mechanisms of Response to COVID Vaccine in Kidney Transplant Recipients | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $452,792 | August 21, 2023 | July 31, 2025 | MALTZMAN, JONATHAN S | reporter.nih.gov |
| Adaptive immune responses in bats | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $452,475 | July 3, 2025 | June 30, 2030 | SCHOUNTZ, WILLIAM A | reporter.nih.gov |
| mRNA vaccine responses in PLWH | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $450,313 | August 22, 2022 | July 31, 2024 | BLANKSON, JOEL N | reporter.nih.gov |
| Vaccine-induced SARS-CoV-2-specific T cell responses in patients with X-linked Agammaglobulinemia | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $445,633 | January 9, 2023 | December 31, 2025 | DE PARIS, KRISTINA | reporter.nih.gov |
| Mechanism of membrane inactivation method to prepare enveloped virus vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $444,397 | June 23, 2021 | May 31, 2024 | AGUILAR-CARRENO, HECTOR | reporter.nih.gov |
| Evaluation of the Impact of HIV Status on the Immune Response to mRNA COVID-19 Vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $444,125 | March 1, 2022 | February 29, 2024 | GANDHI, MONICA | reporter.nih.gov |
| COVID-19, heavy drinking and alcohol use disorders: a national study of Veterans Administration patients | NIH | National Institute on Alcohol Abuse and Alcoholism | 2022 to 2023 | $442,952 | April 1, 2022 | March 31, 2025 | HASIN, DEBORAH S | reporter.nih.gov |
| Structural investigations of coronavirus spike protein | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $442,125 | September 26, 2024 | August 31, 2026 | HASAN, SYED SAIF | reporter.nih.gov |
| Synergizing neutralization and non-neutralization antibody targets at the HIV/SIV viral spike apex | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $440,700 | August 9, 2024 | June 30, 2027 | CARDOZO, TIMOTHY J | reporter.nih.gov |
| COVID19 vaccine hesitancy among perinatal women at risk for health disparities | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 to 2024 | $434,653 | January 1, 2023 | March 10, 2025 | BATTLE, CYNTHIA L. | reporter.nih.gov |
| mRNA COVID-19 Vaccines Delivered with Plant Virus/Polymer Devices | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $434,500 | April 1, 2021 | March 31, 2024 | STEINMETZ, NICOLE FRANZISKA | reporter.nih.gov |
| Broad-based spike protein stalk-based vaccine platform for SARS-CoV-2 and other coronaviruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $431,750 | September 22, 2021 | August 31, 2024 | WHITTAKER, GARY R | reporter.nih.gov |
| Improving the Immune Response to Nanoparticle-Based SARS-CoV-2 Vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $431,750 | September 1, 2023 | August 31, 2025 | WANG, SZU-WEN | reporter.nih.gov |
| Adjuvant combination for SARS-CoV-2 vaccine for the elderly | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $430,375 | July 8, 2022 | September 30, 2024 | VASSILIEVA, ELENA | reporter.nih.gov |
| Vaccine-Induced Mucosal T-Cell Immunity to Respiratory Viruses in Dirty Mice | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $427,625 | August 14, 2023 | July 31, 2025 | SURESH, MARULASIDDAPPA | reporter.nih.gov |
| Structural Basis for T Cell Recognition of SARS-CoV-2 | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $426,381 | August 3, 2023 | July 31, 2025 | MARIUZZA, ROY A | reporter.nih.gov |
| Viral Vectored COVID-19 Vaccines in a Guinea Pig Perinatal Infection Model | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $426,250 | November 1, 2021 | October 31, 2024 | SCHLEISS, MARK R. | reporter.nih.gov |
| The impact of aging and thymus regeneration on tissue-resident CD8 T cell responses to viral lung infection and vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $426,250 | June 1, 2022 | May 31, 2025 | GRIFFITH, ANN VENABLES | reporter.nih.gov |
| Neuroprotective Potential of Vaccination Against SARS-CoV-2 in Nonhuman Primates | NIH | National Institute of Neurological Disorders and Stroke | 2023 | $426,250 | April 15, 2023 | March 31, 2026 | DAUNAIS, JAMES B | reporter.nih.gov |
| Dissecting the mechanism of altered immune responses during obesity | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $425,647 | June 20, 2025 | May 31, 2027 | LEADBETTER, ELIZABETH ANN | reporter.nih.gov |
| Seeing the Unseen: High-Throughput Prospective Profiling and inhibition of SARS-CoV-2 receptor-binding domain variants | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $424,911 | December 8, 2022 | November 30, 2025 | KHARE, SAGAR D | reporter.nih.gov |
| A novel model to study COVID-19 and Hypertension | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $424,875 | June 14, 2021 | May 31, 2023 | JOE, BINA | reporter.nih.gov |
| Pandemic preparedness for underserved persons in the US: Harnessing data from the RADx-UP consortium to assess public health tools for resource allocation | NIH | National Institute on Minority Health and Health Disparities | 2023 to 2024 | $424,600 | September 21, 2023 | June 30, 2025 | ANAND, SHUCHI | reporter.nih.gov |
| Compressed sequential infection regimen to model immune responses to systemic and mucosal vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $421,794 | February 1, 2024 | December 31, 2025 | BALDRIDGE, MEGAN T | reporter.nih.gov |
| A Novel Vaccine Adjuvant KOR-selective Small Molecule Agonist | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $420,730 | July 1, 2024 | May 31, 2026 | YOU, ZHAOYANG | reporter.nih.gov |
| Reducing Vaccine Hesitancy among Hispanic Parents of COVID-19 Vaccine-Eligible Children | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 | $419,796 | September 1, 2023 | March 10, 2025 | KOSKAN, ALEXIS M. | reporter.nih.gov |
| Investigation of sarbecovirus exposure patterns and development of pan-SARS-CoV-2 neutralizing antibody responses in high-risk cohorts in Myanmar | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $419,748 | June 6, 2023 | December 31, 2025 | EVANS, TIERRA SMILEY | reporter.nih.gov |
| High-Throughput, Rapid, and Epitope-Specific Quantification of Neutralizing Antibodies Using Digital Nanoparticle Sensors | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $418,253 | April 20, 2022 | September 30, 2025 | WANG, CHAO | reporter.nih.gov |
| Adjuvant effect of physical exercise on immune response to COVID-19 vaccination and interactions with stress | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $416,127 | September 6, 2023 | August 31, 2025 | KOHUT, MARIAN L | reporter.nih.gov |
| HLA class I peptidome diversities and CD8+ T cell responses to COVID-19 vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $415,560 | June 1, 2022 | May 31, 2026 | RAGHAVAN, MALINI | reporter.nih.gov |
| Per- and Polyfluoroalkyl Substances (PFAS) Exposures and COVID-19 Vaccine Effectiveness | NIH | National Institute of Environmental Health Sciences | 2021 to 2022 | $414,635 | August 16, 2021 | April 30, 2024 | BURGESS, JEFFEREY L. | reporter.nih.gov |
| Improving mRNA vaccines with extracellular vesicle-associated immunogens | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $410,877 | November 9, 2022 | January 31, 2025 | FARZAN, MICHAEL R. | reporter.nih.gov |
| A Multi-site Investigation of Social Determinants of Health and SARS-CoV-2 Testing and Vaccination Outcomes among Diverse US Latinx Adults | NIH | National Institute on Minority Health and Health Disparities | 2023 to 2024 | $407,875 | September 21, 2023 | June 30, 2025 | DE ANDA, STEPHANIE | reporter.nih.gov |
| Mutational Analysis of Tradeoffs between Receptor Affinity and Antibody Escape for SARS-CoV-2 Variants of Concern | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $404,594 | June 16, 2022 | May 31, 2025 | TESSIER, PETER M | reporter.nih.gov |
| The COVID-19 vaccine efficacy among people living with and without HIV: a real-world data approach | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $398,262 | June 10, 2022 | May 31, 2025 | YANG, XUEYING | reporter.nih.gov |
| Serological and functional impact of COVID-19 vaccination on the maternal fetal unit and infant immunity | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2023 | $395,922 | September 1, 2022 | August 31, 2025 | BOELIG, RUPSA CHAUDHURY | reporter.nih.gov |
| Prevalence of Coronaviruses in Wild Rodents | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $394,434 | November 17, 2023 | October 31, 2026 | SCHOUNTZ, WILLIAM A | reporter.nih.gov |
| Mucosal B-cell aging in PLWH | NIH | National Institute on Aging | 2024 | $392,709 | September 26, 2024 | August 31, 2025 | EPELDEGUI, MARTA | reporter.nih.gov |
| Chronic health conditions and uptake of COVID-19 testing and vaccination among Native Americans in the RADx-UP Consortium | NIH | National Institute on Minority Health and Health Disparities | 2023 to 2024 | $391,406 | September 21, 2023 | June 30, 2025 | JANITZ, AMANDA E | reporter.nih.gov |
| Elucidating the impact of immune imprinting on SARS-CoV-2 variant vaccination strategies using a humanized mouse model | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $387,288 | August 15, 2024 | July 31, 2029 | BOWEN, ANTHONY | reporter.nih.gov |
| SARS-CoV-2 immune responses in patients with lymphoma | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $385,776 | August 23, 2024 | July 31, 2029 | CHANG, ANDRES | reporter.nih.gov |
| Psychosocial Stress and Adaptation to the COVID-19 Pandemic in the Latinx Population | NIH | National Institute on Aging | 2021 | $384,408 | September 30, 2018 | May 31, 2023 | SUTIN, ANGELINA R | reporter.nih.gov |
| COVID-19 Vaccine Uptake and Risk Mitigation Behaviors: Understanding the Role of Institutional Trust | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $379,139 | February 9, 2023 | March 10, 2025 | DELEO, ROB | reporter.nih.gov |
| Social Epidemiology of COVID-19 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $375,840 | March 6, 2019 | February 28, 2023 | RICHARDSON, EUGENE THOMAS | reporter.nih.gov |
| Covid-19 transmission, testing, and vaccination dynamics within migrant worker social networks | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $374,670 | March 5, 2024 | January 31, 2027 | SCHNEIDER, JOHN | reporter.nih.gov |
| DNA Nanoparticle Vaccine for COVID-19 | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 | $370,098 | December 21, 2020 | December 20, 2022 | BATHE, MARK | reporter.nih.gov |
| Innovative Multiscale Modeling Techniques for Membrane-Bound Proteins | NIH | National Institute of General Medical Sciences | 2025 | $369,500 | September 1, 2025 | August 31, 2030 | HUANG, YU-MING MINDY | reporter.nih.gov |
| Evaluating Teen-Parent Dynamics in Adolescent COVID-19 Vaccine Acceptance and Uptake | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2023 | $366,573 | August 15, 2022 | March 10, 2025 | REGAN, ANNETTE KARENA | reporter.nih.gov |
| Induction of Broad Sarbecovirus Immunity Via A Vaccine Engineered From SARS-CoV-2 Heptad Repeat 1 | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $363,528 | May 28, 2024 | April 30, 2029 | STAMPFER, SAMUEL DAVID | reporter.nih.gov |
| Oral Antivirals against COVID-19 and Clinical Outcomes in High Risk Populations | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $347,188 | July 12, 2023 | June 30, 2025 | BUTT, ADEEL A | reporter.nih.gov |
| Host-microbe interactions and SARS-CoV-2 susceptibility and symptoms in a novel human challenge model | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $347,000 | July 19, 2023 | February 28, 2025 | KELLY, MATTHEW SCOTT | reporter.nih.gov |
| Rational design and evaluation of novel mRNA vaccines against MERS-CoV | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $339,869 | February 13, 2018 | May 31, 2021 | DU, LANYING | reporter.nih.gov |
| Next Generation Stealth Lipid for the Delivery of mRNA | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $314,347 | September 23, 2025 | August 31, 2026 | HUCKNALL, ANGUS | reporter.nih.gov |
| The Science of COVID-19 Vaccines | NIH | National Institute of General Medical Sciences | 2021 | $312,930 | August 4, 2017 | July 31, 2022 | HERMAN, TIM M. | reporter.nih.gov |
| REAL-TIME SURVEILLANCE OF VACCINE MISINFORMATION FROM SOCIAL MEDIA PLATFORMS | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $300,000 | August 8, 2022 | August 7, 2023 | DU, JINGCHENG | reporter.nih.gov |
| CAPTURING MEDICAL MISINFORMATION IN SOCIAL MEDIA USING AN ADVANCED AI SOLUTION SET | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $300,000 | August 8, 2022 | August 7, 2023 | GHIASSI, MANOOCHEHR | reporter.nih.gov |
| DIGITAL TOOLS AGAINST MISINFORMATION ABOUT INFECTIOUS DISEASE TREATMENTS AND VACCINES | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $299,993 | August 8, 2022 | August 7, 2023 | EDOUARD, KHAI | reporter.nih.gov |
| Memory-promoting Ad vaccine for long-lived protection against SARS-CoV-2 | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $299,983 | January 1, 2021 | July 31, 2022 | HARTIGAN-O'CONNOR, DENNIS J. | reporter.nih.gov |
| Development of a Pan-COVID-19 Vaccine Candidate | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $299,967 | March 13, 2024 | February 28, 2026 | HU, HAITAO | reporter.nih.gov |
| SYSTEMATIC UNDERSTANDING AND ELIMINATION OF MISINFORMATION ONLINE | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $299,964 | August 8, 2022 | August 7, 2023 | NOLAN, JAMES | reporter.nih.gov |
| Preclinical Development of GV-MVA-VLP Vaccines Against COVID-19 | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $299,927 | January 5, 2021 | December 31, 2021 | NEWMAN, MARK | reporter.nih.gov |
| Integrin Activation to Augment SARS-CoV-2 Vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $297,724 | May 1, 2021 | October 31, 2022 | MARATHI, UPENDRA | reporter.nih.gov |
| Large scale in vitro production of capped polyadenylated mRNA-based vaccines in solid phase using immobilized enzymes | NIH | National Center for Advancing Translational Sciences | 2021 | $297,193 | September 23, 2021 | September 22, 2023 | KIREEVA, MARIA | reporter.nih.gov |
| Determining the impact of COVID-19 vaccination on the menstrual cycle | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 | $296,124 | December 22, 2016 | June 30, 2022 | EDELMAN, ALISON B | reporter.nih.gov |
| Capless mRNA for use as a vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $294,877 | May 8, 2024 | April 30, 2025 | FOUTY, BRIAN W | reporter.nih.gov |
| Identification of the HIV Reservoir in Lymph Nodes Using Single Cell RNA-Seq | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $284,878 | February 15, 2018 | January 31, 2025 | SIGAL, ALEXANDER | reporter.nih.gov |
| Implementation of a qPCR-based assay for the quantification of SARS-CoV-2-specific T cells in immunocompromised patients | NIH | National Cancer Institute | 2023 | $280,223 | September 18, 2023 | August 31, 2024 | GUCCIONE, ERNESTO | reporter.nih.gov |
| RNA-based multi-antigen vaccine for SARS-CoV-2 | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $278,957 | May 1, 2021 | October 31, 2022 | MANDL, CHRISTIAN W. | reporter.nih.gov |
| Targeting lipid-oxidizing B cells to enhance vaccine responses during immunosuppression | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $270,000 | September 1, 2024 | August 31, 2026 | THOMPSON, ELIZABETH ANNE | reporter.nih.gov |
| Navajo NARCH Partnership | NIH | National Institute of General Medical Sciences | 2021 | $268,995 | September 15, 2017 | July 31, 2022 | BAUER, MARK C | reporter.nih.gov |
| Defining antiviral T cell responses restricted to the non-classical MHC class Ib molecule, Qa-1 | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $268,205 | June 1, 2024 | May 31, 2026 | HOGAN, MICHAEL JOHN | reporter.nih.gov |
| Effects of Exogenous Hormone Treatment on Vaccine Responses | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $267,121 | December 16, 2024 | November 30, 2026 | LUSTIGMAN, SARA | reporter.nih.gov |
| Tobacco-based Sustainable Squalene for Novel Vaccine Adjuvant Emulsions | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $257,003 | August 15, 2022 | July 31, 2023 | GORMAN, CONNOR R. | reporter.nih.gov |
| Improving influenza vaccines through wastewater-based macro-scale strain surveillance | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $256,575 | February 1, 2022 | July 31, 2022 | KANE, SARAH JO | reporter.nih.gov |
| Identification and characterization of gut microbial bioactive molecules that determine predisposition to autoimmune disease and atopy | NIH | National Center for Complementary & Integrative Health | 2021 | $253,500 | April 1, 2017 | March 31, 2022 | CLARDY, JON | reporter.nih.gov |
| SARS-CoV-2 and Respiratory Virus Co-Infections Among Young Children | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $234,541 | June 13, 2024 | April 30, 2027 | REGAN, ANNETTE KARENA | reporter.nih.gov |
| Mentoring translational researchers in perinatal infectious diseases | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $205,999 | December 4, 2024 | November 30, 2029 | GAW, STEPHANIE LINA | reporter.nih.gov |
| COVID-19 Vaccine Coverage and General Vaccine Hesitancy in Rural Areas in the United States | NIH | National Institute on Minority Health and Health Disparities | 2024 | $196,875 | August 24, 2024 | April 1, 2025 | REITER, PAUL L | reporter.nih.gov |
| Defining vaccine immunogenicity and adoptive transfer in hematopoietic stem cell transplant recipients | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $194,400 | September 15, 2025 | August 31, 2029 | SHERMAN, AMY CARYN | reporter.nih.gov |
| Frontiers in Cancer Research (SEPA Supplement) | NIH | National Institute of General Medical Sciences | 2021 | $188,621 | August 1, 2018 | June 30, 2023 | CHOWNING, JEANNE TING | reporter.nih.gov |
| Legacy of Obesity on Influenza and Coronavirus | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $182,000 | November 1, 2021 | October 31, 2023 | SCHULTZ-CHERRY, STACEY L | reporter.nih.gov |
| Determinants of Vaccine Responses in Low-Income Countries (LICs) | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $176,738 | September 1, 2025 | August 31, 2030 | VALIM, CLARISSA | reporter.nih.gov |
| SARS-CoV-2 and respiratory virus co-infections among young children | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $175,556 | June 13, 2024 | April 30, 2026 | REGAN, ANNETTE KARENA | reporter.nih.gov |
| Hospital-Associated Respiratory Virus Infections: Molecular Epidemiology, Clinical Outcomes, and Cost-Effectiveness of Interventions - COVID-19 Administrative Supplement | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $166,214 | January 2, 2019 | December 31, 2021 | PETRIE, JOSHUA GLENN | reporter.nih.gov |
| Development of a stable mRNA prophylactic vaccine against SARS-CoV-2 omicron variant | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $161,500 | August 18, 2025 | July 31, 2027 | MAI, JUNHUA | reporter.nih.gov |
| Giant MagnetoResistive (GMR) Sensors for Measuring Influenza Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $158,000 | August 1, 2020 | July 31, 2022 | UTZ, PAUL JOSEPH | reporter.nih.gov |
| Induction and maintenance of SARS-CoV-2 mRNA vaccine-specific memory across tissues | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $154,682 | July 1, 2023 | June 30, 2027 | DAVIS-PORADA, JULIA MEGHAN | reporter.nih.gov |
| Developing Lectins as Inhibitors of Coronavirus Spike Proteins | NIH | National Institute of General Medical Sciences | 2022 to 2023 | $152,084 | September 1, 2022 | January 31, 2024 | GUSEMAN, ALEX JOSEPH | reporter.nih.gov |
| Developing a liquid formulation for CVXGA1 COVID-19 intranasal vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $150,000 | August 1, 2022 | January 31, 2024 | LI, ZHUO | reporter.nih.gov |
| Transcriptional variation in human milk | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2024 to 2025 | $147,600 | January 1, 2024 | December 31, 2026 | NYQUIST, SARAH KATE | reporter.nih.gov |
| Determining the role of antibody epitope specificity in regulating Fc effector functions | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $128,461 | August 1, 2025 | July 31, 2027 | COHEN, ALEXANDER A | reporter.nih.gov |
| Identifying and evaluating prevention strategies for COVID-19 in correctional facilities | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $126,820 | August 4, 2023 | August 2, 2024 | LIND, MARGARET | reporter.nih.gov |
| A computational modeling framework for COVID-19 vaccination | NIH | National Institute of General Medical Sciences | 2021 | $122,580 | September 1, 2019 | August 31, 2023 | WANG, JIN | reporter.nih.gov |
| Regulation and Function of respiratory mucosal immunity post SARS-CoV-2 vaccination and infection | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $108,273 | September 3, 2025 | August 31, 2027 | TANG, JINYI | reporter.nih.gov |
| Molemolemo: Building Research Administration Excellence in South Africa | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $108,000 | April 21, 2022 | June 30, 2024 | VAN DER WIND, DAPHNE | reporter.nih.gov |
| Structure-based design of coronavirus subunit vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $102,509 | May 21, 2018 | May 31, 2021 | DU, LANYING | reporter.nih.gov |
| RANKL regulation of human B cell responses | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $88,360 | July 1, 2025 | June 30, 2026 | KOTZIN, JONATHAN J | reporter.nih.gov |
| Understanding spillover potential of European and African bat sarbecoviruses | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $87,970 | January 1, 2023 | December 31, 2024 | ZEPEDA, SAMANTHA KATHLEEN | reporter.nih.gov |
| Identifying Vulnerable Communities for Infectious Disease Outbreaks | NIH | National Institute on Minority Health and Health Disparities | 2022 to 2023 | $85,874 | July 1, 2022 | March 17, 2024 | SRIVASTAVA, TUHINA | reporter.nih.gov |
| Improving mRNA vaccines with extracellular vesicle-associated immunogens | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $82,817 | November 9, 2022 | February 28, 2023 | FARZAN, MICHAEL R. | reporter.nih.gov |
| Identifying individual and community factors associated with high COVID-19 incidence and mortality rates among people with HIV. | NIH | National Institute on Minority Health and Health Disparities | 2023 to 2024 | $78,118 | May 9, 2023 | April 30, 2025 | GWANZURA, TENDAI NOMHLE RUMBIDZAI | reporter.nih.gov |
| Notch2 Amplification of B Cell Division and Differentiation Fates | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $73,888 | August 1, 2024 | July 31, 2026 | LONDREGAN, JENNIFER | reporter.nih.gov |
| Enriched environments: a multi-level integrative medicine intervention for endometriosis | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 | $60,838 | July 1, 2021 | June 30, 2023 | FLORES, IDHALIZ | reporter.nih.gov |
| GENES AND MICROBES: NGSS-ALIGNED CURRICULA FOR SECONDARY SCIENCE | NIH | National Institute of General Medical Sciences | 2021 | $54,000 | June 1, 2016 | May 31, 2022 | STARK, LOUISA A | reporter.nih.gov |
| Antibody feedback on B cell response to vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $36,673 | July 1, 2025 | June 30, 2029 | EVAVOLD, BIRK | reporter.nih.gov |
| Vaccinology During and After COVID-19 | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $7,500 | July 20, 2023 | June 30, 2024 | SHEPPARD, TERRY L. | reporter.nih.gov |
| 2023 Physical Virology GRC and GRS | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $6,500 | December 12, 2022 | April 30, 2023 | HAGAN, MICHAEL F | reporter.nih.gov |
| 2023 International Society for Vaccines (ISV) Annual Congress, October 22-25, Lausanne, Switzerland | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $5,000 | August 22, 2023 | July 31, 2024 | WEINER, DAVID B. | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| Fred Hutchinson Cancer Research Center | Seattle, WA | 4 | $269 million | 0 | $0 |
| Icahn School of Medicine at Mount Sinai | New York, NY | 10 | $34.6 million | 0 | $0 |
| Duke University | Durham, NC | 2 | $21 million | 0 | $0 |
| New Mexico State University | Las Cruces, NM | 1 | $20.7 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 7 | $18.8 million | 0 | $0 |
| Stanford University | Stanford, CA | 6 | $17.1 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 9 | $13 million | 0 | $0 |
| University of Houston | Houston, TX | 1 | $12.9 million | 0 | $0 |
| La Jolla Institute for Immunology | La Jolla, CA | 1 | $12.6 million | 0 | $0 |
| Univ of North Carolina Chapel Hill | Chapel Hill, NC | 5 | $12.1 million | 0 | $0 |
| Louisiana State Univ HSC Shreveport | Shreveport, LA | 1 | $12.1 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 8 | $10.4 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 7 | $10.4 million | 0 | $0 |
| Yale University | New Haven, CT | 6 | $10.3 million | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 6 | $9.9 million | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 6 | $9.5 million | 0 | $0 |
| Idt Biologika GMBH | Dessau-Rosslau | 1 | $8.6 million | 0 | $0 |
| Weill Medical Coll of Cornell Univ | New York, NY | 2 | $8.3 million | 0 | $0 |
| University of California Los Angeles | Los Angeles, CA | 6 | $8.1 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 6 | $7.6 million | 0 | $0 |
| Columbia University Health Sciences | New York, NY | 5 | $7.2 million | 0 | $0 |
| University of Maryland Baltimore County | Baltimore, MD | 1 | $7.1 million | 0 | $0 |
| Scripps Research Institute, the | La Jolla, CA | 3 | $7 million | 0 | $0 |
| Vaccine Formulation Institute (CH) LTD | Plan-Les-Ouates | 1 | $6.9 million | 0 | $0 |
| Emory University | Atlanta, GA | 7 | $6.9 million | 0 | $0 |
| HDT Bio Corporation | Seattle, WA | 1 | $6.7 million | 0 | $0 |
| University of Colorado Denver | Aurora, CO | 3 | $6.4 million | 0 | $0 |
| University of Chicago | Chicago, IL | 2 | $6.2 million | 0 | $0 |
| Boston Children's Hospital | Boston, MA | 3 | $5.8 million | 0 | $0 |
| Boston University Medical Campus | Boston, MA | 4 | $5.5 million | 0 | $0 |
| Kaiser Foundation Research Institute | Oakland, CA | 3 | $5.1 million | 0 | $0 |
| University of California-Irvine | Irvine, CA | 3 | $4.7 million | 0 | $0 |
| Deloitte Consulting, LLP | Arlington, VA | 1 | $4.3 million | 0 | $0 |
| University of Wisconsin-Madison | Madison, WI | 2 | $4.1 million | 0 | $0 |
| Colorado State University | Fort Collins, CO | 3 | $4 million | 0 | $0 |
| Washington University | Saint Louis, MO | 4 | $4 million | 0 | $0 |
| Henry M. Jackson FDN for the Adv Mil/med | Bethesda, MD | 1 | $3.8 million | 0 | $0 |
| Rand Corporation | Santa Monica, CA | 2 | $3.7 million | 0 | $0 |
| Univ of Massachusetts Med SCH Worcester | Worcester, MA | 2 | $3.7 million | 0 | $0 |
| Emmune, INC | Juno Beach, FL | 1 | $3.3 million | 0 | $0 |
| Graduate School of Public Health and Health Policy | New York, NY | 1 | $3.3 million | 0 | $0 |
| New York University School of Medicine | New York, NY | 2 | $3.2 million | 0 | $0 |
| Ohio State University | Columbus, OH | 4 | $3.2 million | 0 | $0 |
| University of Virginia | Charlottesville, VA | 3 | $3.2 million | 0 | $0 |
| University of Florida | Gainesville, FL | 2 | $3.1 million | 0 | $0 |
| Purdue University | West Lafayette, IN | 1 | $3.1 million | 0 | $0 |
| Rockefeller University | New York, NY | 1 | $3 million | 0 | $0 |
| Enepret, Inc. | Lexington, KY | 1 | $3 million | 0 | $0 |
| University of Maryland Baltimore | Baltimore, MD | 5 | $2.9 million | 0 | $0 |
| University of Miami School of Medicine | Coral Gables, FL | 2 | $2.9 million | 0 | $0 |
| Northeastern University | Boston, MA | 1 | $2.9 million | 0 | $0 |
| Georgia State University | Atlanta, GA | 2 | $2.8 million | 0 | $0 |
| Southcentral Foundation | Anchorage, AK | 1 | $2.7 million | 0 | $0 |
| New York University | New York, NY | 2 | $2.7 million | 0 | $0 |
| Orlance, Inc. | Seattle, WA | 2 | $2.6 million | 0 | $0 |
| Thomas Jefferson University | Philadelphia, PA | 2 | $2.5 million | 0 | $0 |
| Fluid Synchrony, LLC | Pasadena, CA | 1 | $2.5 million | 0 | $0 |
| University of Kentucky | Lexington, KY | 1 | $2.5 million | 0 | $0 |
| Northwestern University at Chicago | Chicago, IL | 1 | $2.2 million | 0 | $0 |
| Cornell University | Ithaca, NY | 3 | $2.2 million | 0 | $0 |
| Michigan State University | East Lansing, MI | 1 | $2.2 million | 0 | $0 |
| University of Oxford | Oxford | 1 | $2.1 million | 0 | $0 |
| Mayo Clinic Rochester | Rochester, MN | 2 | $2.1 million | 0 | $0 |
| Fred Hutchinson Cancer Center | Seattle, WA | 1 | $2.1 million | 0 | $0 |
| Healthpartners Institute | Bloomington, MN | 1 | $2 million | 0 | $0 |
| University of Texas Med BR Galveston | Galveston, TX | 1 | $2 million | 0 | $0 |
| University of Alabama at Birmingham | Birmingham, AL | 1 | $1.9 million | 0 | $0 |
| Tendel Therapies Inc. | Kensington, CA | 2 | $1.9 million | 0 | $0 |
| San Diego State University Foundation | San Diego, CA | 1 | $1.9 million | 0 | $0 |
| Medical College of Wisconsin | Milwaukee, WI | 1 | $1.9 million | 0 | $0 |
| Wake Forest University Health Sciences | Winston-Salem, NC | 2 | $1.8 million | 0 | $0 |
| Florida State University | Tallahassee, FL | 2 | $1.8 million | 0 | $0 |
| University of San Francisco | San Francisco, CA | 3 | $1.8 million | 0 | $0 |
| Rutgers Biomedical and Health Sciences | Newark, NJ | 1 | $1.8 million | 0 | $0 |
| University of Washington | Seattle, WA | 3 | $1.7 million | 0 | $0 |
| Boston College | Chestnut Hill, MA | 1 | $1.7 million | 0 | $0 |
| Accel Diagnostics, LLC | Houston, TX | 1 | $1.7 million | 0 | $0 |
| Ut Southwestern Medical Center | Dallas, TX | 1 | $1.7 million | 0 | $0 |
| University of Illinois at Urbana-Champaign | Urbana, IL | 1 | $1.6 million | 0 | $0 |
| Massachusetts General Hospital | Boston, MA | 1 | $1.6 million | 0 | $0 |
| J. David Gladstone Institutes | San Francisco, CA | 2 | $1.6 million | 0 | $0 |
| Soligenix, Inc. | Princeton, NJ | 1 | $1.5 million | 0 | $0 |
| Texas A&M Engineering Experiment Station | College Station, TX | 1 | $1.4 million | 0 | $0 |
| University of Iowa | Iowa City, IA | 1 | $1.3 million | 0 | $0 |
| University of Texas HLTH Sci CTR Houston | Houston, TX | 2 | $1.3 million | 0 | $0 |
| Vanderbilt University Medical Center | Nashville, TN | 1 | $1.3 million | 0 | $0 |
| Family Health International | Durham, NC | 1 | $1.1 million | 0 | $0 |
| Codagenix, Inc. | Farmingdale, NY | 1 | $999,267 | 0 | $0 |
| California Institute of Technology | Pasadena, CA | 2 | $970,461 | 0 | $0 |
| University of Texas HLTH Science Center | San Antonio, TX | 2 | $851,897 | 0 | $0 |
| Arizona State University | Scottsdale, AZ | 2 | $838,049 | 0 | $0 |
| Dana-Farber Cancer Inst | Boston, MA | 1 | $816,829 | 0 | $0 |
| Children's Hospital of Los Angeles | Los Angeles, CA | 1 | $800,606 | 0 | $0 |
| Rbhs-Robert Wood Johnson Medical School | Piscataway, NJ | 1 | $784,970 | 0 | $0 |
| Loyola University Chicago | Maywood, IL | 1 | $755,225 | 0 | $0 |
| New York Blood Center | New York, NY | 3 | $709,499 | 0 | $0 |
| Schepens Eye Research Institute | Boston, MA | 1 | $668,569 | 0 | $0 |
| Harvard Medical School | Boston, MA | 2 | $629,340 | 0 | $0 |
| University of Texas at Austin | Austin, TX | 1 | $613,032 | 0 | $0 |
| Adjuvax LLC | Hoover, AL | 1 | $600,000 | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 121 | $75,104,061 | 0 | $0 |
| 2024 | 158 | $104,108,728 | 0 | $0 |
| 2023 | 158 | $120,042,184 | 0 | $0 |
| 2022 | 140 | $130,807,870 | 0 | $0 |
| 2021 | 100 | $336,591,270 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|---|---|---|---|---|---|
| NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed) | PA-24-194 | NIH | May 7, 2027 | Not listed | Notice number printed on 2 awards here | |
| Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed) | PA-24-185 | NIH | May 7, 2027 | Not listed | Notice number printed on 1 award here | |
| Change of Recipient Organization (Type 7 Parent Clinical Trial Optional) | PA-24-254 | NIH | July 12, 2027 | Not listed | Notice number printed on 1 award here | |
| Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required) | RFA-AI-27-002 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 181 awards here |
| Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required) | RFA-AI-27-005 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 181 awards here |
| Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional) | PAR-25-370 | NIH | 93.855 | November 16, 2026 | $50,000 | Same assistance listing 93.855 as 181 awards here |
| Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional) | PAR-25-369 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 181 awards here |
| Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional) | PAR-25-371 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 181 awards here |
| Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) | PAR-25-379 | NIH | 93.855 | January 7, 2027 | Not listed | Same assistance listing 93.855 as 181 awards here |
| HIV/AIDS Clinical Trials Network Leadership and Operations Centers | RFA-AI-28-001 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 181 awards here |
| HIV/AIDS Clinical Trials Network Laboratory Centers | RFA-AI-28-002 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 181 awards here |
| HIV/AIDS Clinical Trials Network Statistical and Data Management Centers | RFA-AI-28-003 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 181 awards here |
| HIV/AIDS Clinical Trials Network Clinical Trials Units | RFA-AI-28-004 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 181 awards here |
| Precision and Systems Biology to Uncover the Link Between Chronic and Infectious Diseases | RFA-AI-28-014 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 181 awards here |
| Immune Tolerance Network (UM1 Clinical Trial Required) | RFA-AI-28-005 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 181 awards here |
| Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed) | RFA-AI-28-012 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 181 awards here |
| Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed) | RFA-AI-28-024 | NIH | 93.855 | February 11, 2027 | Not listed | Same assistance listing 93.855 as 181 awards here |
| NLM Institutional Grants for Research Training in Biomedical Informatics, Data Science, and AI (T15 Independent Clinical Trial Not Allowed) | RFA-LM-28-001 | NIH | 93.855 | February 11, 2027 | $775,000 | Same assistance listing 93.855 as 181 awards here |
| NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) | PA-27-100 | NIH | 93.855 | April 5, 2027 | Not listed | Same assistance listing 93.855 as 181 awards here |
| NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional) | PA-27-102 | NIH | 93.855 | April 5, 2027 | Not listed | Same assistance listing 93.855 as 181 awards here |
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.